Innovent, Hutchison MediPharma in Drug Combo Collaboration

Innovent Biologics, Inc. a China-based biopharmaceutical company has entered into a global collaboration agreement with Hutchison China MediTech to evaluate the safety and tolerability of Innovent's sintilimab in combination with Hutchison MediPharma's fruquintinib in patients with advanced solid tumors. 
 
Innovent and Hutchison MediPharma will jointly explore potential application of this combination in solid tumors with global unmet medical needs through development efforts both in the U.S. and in China.
 
"We are two leading China-based biopharmaceutical companies, one specialized in small molecules and another in large molecules; and we share the same vision of bringing China-originated mainstream anti-cancer therapies to global patients by combining our expertise and resources," said Dr. Michael Yu, chief executive officer and chairman of Innovent. "There is strong scientific evidence supporting synergistic effects of PD-1 therapy when used in combination with VEGFR inhibitor. In addition, we hope to benefit from recent regulatory changes in China that allow for the recognition of foreign clinical trial data to possibly expedite the path to a China launch. We are very pleased to partner with Chi-Med to co-develop this novel combination therapy for global patients."

-----------------------------------------------------------------------

Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.